Detection and evaluation of epithelial cells in the blood of colon cancer patients using RT-PCR

Katsumata, Kenji; Sumi, Toshiyuki; Mori, Yoichiro; Hisada, Masayuki; Tsuchida, Akihiko; Aoki, Tatsuya

doi:10.1007/s10147-006-0590-5

Cited by 30 publications

(32 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the clinical significance of CTCs from patients with tumors is still debatable (12,13), the technology platform has improved rapidly. Over the last few years, CTC detection has become more standardized and reliable (14,15).…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients

Wong

Chan

Yue

et al. 2009

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Current immunomagnetic enrichment method can only detect general epithelial antigens of circulating tumor cells (CTC). Further characterization of the CTCs to provide specific information on the tumor type is not possible.We attempted to overcome this drawback by developing the methodology for using a gastrointestinal-specific anti-cytokeratin (CK) 20 antibody to detect CTCs in colorectal cancer patients' blood. Experimental Design: The protocol was validated using a colorectal cancer SW480 cell line. The clinical significance of findings in colorectal cancer was investigated by detecting CK20-positive CTCs (pCTC) in patients with colorectal cancer, other common cancers, colorectal adenoma, benign colorectal diseases, and normal subjects. Moreover, the malignant nature of CK20 pCTCs was examined by comparing chromosome 17 aberration patterns with those from the corresponding primary tumors. Results: The assay successfully showed CK20-positive SW480 cells. When applied in patient samples, the detection rates were 62% (132 colorectal cancer patients; median number = 11 CTCs), 0% (120 patients with other common cancers), 6% (50 colorectal adenoma patients), 0% (120 patients with benign colorectal diseases), and 0% (40 normal subjects). Furthermore, statistical analysis showed that CK20 pCTC numbers were associated with tumor-node-metastasis stage and lymph node status. Using the median CK20 pCTC numbers as the cutoff points, stratified groups of colorectal cancer patients had significant differences in their recurrence, metastasis, and survival. Finally, chromosome 17 aneusomy in 90% of colorectal cancer patients with CK20 pCTCs matched with those from the primary tumors. Conclusions: Detection of CK20 pCTCs using the new protocol could generate clinically important information for colorectal cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients

Wong

Chan

Yue

et al. 2009

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…The 14 studies included here comprised 1841 patients in total, with the median number of patients in each study being 99.5 (range 42 -438) (Taniguchi et al, 2000;Yamaguchi et al, 2000;Ito et al, 2002;Bessa et al, 2003;Chen et al, 2004;Sadahiro et al, 2005Sadahiro et al, , 2007Katsumata et al, 2006;Koch et al, 2006;Lloyd et al, 2006;Allen-Mersh et al, 2007;Uen et al, 2007Uen et al, , 2008Wang et al, 2007).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Of the 14 studies included, eight undertook blood sampling perioperatively (Taniguchi et al, 2000;Yamaguchi et al, 2000;Ito et al, 2002;Chen et al, 2004;Sadahiro et al, 2005;Katsumata et al, 2006;Koch et al, 2006;Lloyd et al, 2006), four undertook sampling approximately 24 h after resection (Bessa et al, 2003;Koch et al, 2006;Lloyd et al, 2006;Allen-Mersh et al, 2007), and six undertook sampling between 24 h and 14 days after resection (Chen et al, 2004; Allen-Mersh et al, 2007;Sadahiro et al, 2007;Uen et al, 2007Uen et al, , 2008Wang et al, 2007).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Seven investigated the role of CTC in patients with stage-I to stage-III disease undergoing potentially curative surgery (Ito et al, 2002;Bessa et al, 2003;Sadahiro et al, 2005Sadahiro et al, , 2007Allen-Mersh et al, 2007;Wang et al, 2007;Uen et al, 2008); three studied CTC in patients with early CRC (of which two investigated stage-II disease alone (Koch et al, 2006;Uen et al, 2007) and one investigated stage-I and stage-II disease (Lloyd et al, 2006)); and four papers included patients with stage-I to stage-IV disease (Taniguchi et al, 2000;Yamaguchi et al, 2000;Chen et al, 2004;Katsumata et al, 2006).…”

Section: Tumour Stagementioning

confidence: 99%

“…Of the 14 studies included in our analysis, 10 involved sampling of peripheral blood only (Ito et al, 2002;Bessa et al, 2003;Chen et al, 2004;Katsumata et al, 2006;Lloyd et al, 2006;Allen-Mersh et al, 2007;Sadahiro et al, 2007;Uen et al, 2007Uen et al, , 2008Wang et al, 2007); 1 used peripheral and portal blood samples (Sadahiro et al, 2005); 1 used peripheral and mesenteric samples (Yamaguchi et al, 2000); 1 used peripheral, portal and mesenteric samples (Taniguchi et al, 2000); and 1 used samples of central venous blood (Koch et al, 2006).…”

Section: Blood Sampling Sitementioning

confidence: 99%

See 2 more Smart Citations

Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review

et al. 2010

View full text Add to dashboard Cite

Background: The role of adjuvant chemotherapy after resection of colorectal cancers (CRCs) is well understood for patients with stage-I or stage-III disease. Its efficacy for those with stage-II disease remains much less clear. Many investigators have sought to identify prognostic markers that might clarify which patients have the highest risk of recurrence and would, therefore, be most likely to benefit from chemotherapy. This systematic review examines evidence for the use of peripherally sampled, circulating tumour cells (CTCs) as such a prognostic marker. Methods: A comprehensive literature search was used to identify studies reporting on the significance of CTCs in the postoperative blood of CRC patients. Results: Fourteen studies satisfied the inclusion criteria. Six of the nine studies that took blood samples 24 h or more postoperatively found detection of postoperative CTCs to be an independent predictor of cancer recurrence. Conclusion: The presence of CTCs in peripheral blood at least 24 h after resection of CRCs is an independent prognostic marker of recurrence. Further studies are needed to clarify the optimal time point for blood sampling and determine the benefit of chemotherapy in CTC-positive patients with stage-II disease.

show abstract

Molecular Markers in Circulating Tumour Cells: Advancing Clinical Precision

Tieng,

Osman,

Abdullah-Zawawi

et al. 2024

Interdisciplinary Cancer Research

View full text Add to dashboard Cite

Detection and evaluation of epithelial cells in the blood of colon cancer patients using RT-PCR

Abstract: These findings indicate that CK20 is strongly related to lymph node metastasis and prognosis, suggesting its usefulness for the diagnosis of colorectal cancer recurrence. However, CK20 did not predict liver metastasis.

Cited by 30 publications

References 10 publications

Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients

Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients

Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review

Molecular Markers in Circulating Tumour Cells: Advancing Clinical Precision

Contact Info

Product

Resources

About